1
Back
E

Expert Opinion on Investigational Drugs

IF4.1
Papers3443
Citations5734
Journal Papers 3554
Publication Date
delete
Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-16
delete0
PREAI
deleteMarie Kroemer; Morgane Lopez; Laura Mansi; Elsa Curtit
deleteShare
deleteSave
Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-16
delete0
PREAI
deleteLuigi Francesco Iannone; Marina Romozzi; Luca Pani; Fabio Tascedda
deleteShare
deleteSave
The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-14
delete0
deleteOAAI
deleteStephen J. Walsh; Francesca Wood; Leslie R. DeMars; Gavin Bennett
deleteShare
deleteSave
Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-09
delete0
PREAI
deleteHui Qiu; Xingfei Zhang; Jie Huang; Lin Ye; Chan Zou; Jinlian Xie; Kunhong Deng; Qian Wu; Xiulin He; Congxin Liang; Yong Liu; Guang Yang; Guoping Yang; Chengxian Guo
deleteShare
deleteSave
The impact of novel BET inhibitors on the treatment armamentarium of myelofibrosis
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-08
delete0
PREAI
deleteMatteo Bellia; Clara Deambrogi; Abdurraouf Mokhtar Mahmoud; Andrea Patriarca
deleteShare
deleteSave
Alpha-1 antitrypsin: therapeutic applications beyond serine protease inhibition
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-03
delete0
PREAI
deleteMartina Toldo; Trushaben Patel; Michele Golino; Eugenio Refrigeri; Jazmin Kelly; Antonio Abbate; Eleonora Mezzaroma; Stefano Toldo
deleteShare
deleteSave
SOT201: cis-acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-03
delete0
PREAI
deleteVladyslav Mazhara; Irfan Baki Kilic; Irena Adkins; Radek Spisek; Marek Kovar
deleteShare
deleteSave
A novel sequential ketamine and D-cycloserine/lurasidone therapy for bipolar depression with acute suicidal ideation
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-05-26
delete0
deleteOAAI
deleteMina Takahashi; Richard C. Shelton
deleteShare
deleteSave
GV1001: repurposing a telomerase-derived peptide for neurological therapeutics
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-05-18
delete0
PREAI
deleteKyoungho Suk; Won-Ha Lee
deleteShare
deleteSave
New insights into the management of Behçet syndrome
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-05-18
delete0
PREAI
deleteSinem Nihal Esatoglu; Yesim Ozguler; Gulen Hatemi
deleteShare
deleteSave
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-05-04
delete0
PREAI
deleteYuxin Liu; Clifton Mo; Shonali Midha; Monique Hartley-Brown; Hans C. Lee; Joseph Franz; Omar Nadeem; Taylor Nicholson; Taya Jamal Salman; Anne Fortune; Robert Rifkin; Lauren E. Merz; Jesus Berdeja; Jacob Laubach; Peter O’Gorman; Paul G. Richardson
deleteShare
deleteSave
Innovative therapies under clinical development for ALS treatment: small molecules
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-05-03
delete0
PREAI
deleteLoreto Martinez-Gonzalez; Cecilia Sanchez-Santos; Chi-Chen Sarah Huang; Carmen Gil; Ana Martinez
deleteShare
deleteSave
Discontinued therapies for sickle cell disease: status and future directions
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-04-23
delete0
PREAI
deleteAkshay Sharma; Shruthi Suryaprakash; Liza-Marie Johnson; Yoram Unguru
deleteShare
deleteSave
Targeting cutaneous T-cell lymphoma in non-Hodgkin lymphoma: what’s new for investigational agents?
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-04-21
delete0
PREAI
deleteNeha Akkad; Auris Huen; Swaminathan P. Iyer
deleteShare
deleteSave
Tafoxiparin effects on cervical ripening and labor augmentation
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-04-20
delete0
PREAI
deleteValentina Tosto; Carolina Scala; Ambrogio Pietro Londero; Federico Prefumo
deleteShare
deleteSave
ANGPTL3 gene editing with CRISPR-Cas9: early trial insights
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-04-13
delete0
deleteOAAI
deleteXuan L. Tang; Amanda J. Hooper; John R. Burnett
deleteShare
deleteSave
Clinical development of a CDK8/19 kinase inhibitor for acute myeloid leukemia
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-04-07
delete0
deleteOAAI
deleteAkhil Rajendra; Karen W. L. Yee
deleteShare
deleteSave
Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-03-12
delete0
PREAI
deleteM. Abdullah Jamil; Salman Otoukesh; Haris Ali
deleteShare
deleteSave
Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-03-11
delete0
PREAI
deletePremal H. Thaker; Stacy R. Lindborg; Ana Limon; Douglas V. Faller; William H. Bradley; Khursheed Anwer; Ronald D. Alvarez
deleteShare
deleteSave
Tubulin polymerization inhibitors in early clinical studies as cancer therapeutics
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-03-10
delete0
PREAI
deleteAhmed Kamal; Rahaman Shaik; Prasanna Anjaneyulu Yakkalaa
deleteShare
deleteSave